🇺🇸 FDA
Patent

US 12138312

Cell-penetrating peptides for antisense delivery

granted A61KA61K31/713A61K38/00

Quick answer

US patent 12138312 (Cell-penetrating peptides for antisense delivery) held by Sarepta Therapeutics, Inc. expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/713, A61K38/00, A61K47/645, A61K47/6455